US5164302A - Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives - Google Patents
Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives Download PDFInfo
- Publication number
- US5164302A US5164302A US07/436,582 US43658289A US5164302A US 5164302 A US5164302 A US 5164302A US 43658289 A US43658289 A US 43658289A US 5164302 A US5164302 A US 5164302A
- Authority
- US
- United States
- Prior art keywords
- pregnene
- hydroxy
- dione
- derivatives
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 11
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 241000228417 Sarocladium strictum Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 10
- 230000024245 cell differentiation Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000016087 ovulation Effects 0.000 abstract description 4
- 150000003145 progesterone derivatives Chemical class 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 150000003130 pregnenes Chemical class 0.000 description 8
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/06—Hydroxylating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Definitions
- This invention relates to novel pregnene derivatives used as intermediates for the synthesis of progesterone derivatives having ovulation-inhibiting activity.
- a group of these compounds is expected to be used in the field of medicine.
- Cell differentiation activity is also found on a part of these compounds and hence utilization as drugs is also expected in this area.
- pregnene derivatives of this invention are novel compounds and biological activities of these compounds have naturally been unknown.
- the present inventors have researched the action of microorganisms belonging to Acremonium sp., e.g. a strain of mold fungi, in a substrate of 4-pregnene- 3,20-dione. As a result, it has been found that two types of novel pregnene derivatives specified in this invention are produced.
- the present inventors have further subjected one of the derivatives produced above to a reaction with acid anhydrides and found that esters of these derivatives can be obtained.
- the pregnene derivatives of this invention can be used as intermediates for the manufacture of -TMprogesterone derivatives. These pregnene derivatives including the above mentioned esters exhibit also cell differentiation activity.
- FIGS. 1-4 relate to the 1st compound of this invention.
- FIG. 1 illustrates an EI mass spectrum.
- FIG. 2 shows an infrared absorption spectrum.
- FIG. 3 shows a proton nuclear magnetic resonance spectrum.
- FIG. 4 illustrates a 13 C-nuclear magnetic resonance spectrum.
- FIGS. 5-7 relate to the 2nd compound of this invention.
- FIG. 5 illustrates an EI mass spectrum.
- FIG. 6 illustrates a proton nuclear magnetic resonance spectrum.
- FIG. 7 shows a 13 C-nuclear magnetic resonance spectrum.
- This invention is to provide a novel pregnene derivatives which is used as an intermediate for the manufacture of progesterone derivatives having progestin activities such as ovulation-inhibiting activity and also has itself cell differentiation activity.
- This invention will hereinafter be illustrated in detail by way of examples.
- 4-Pregnene 3,20-dione as a substrate was dissolved in dimethylformamide in advance so as to obtain a substrate concentration of 0.1 g/ml.
- a crude fraction thus obtained was dissolved in a small amount of chloroform (or methanol) and passed through a silica gel column HPLC (20 mm diameter ⁇ 300 mm length).
- the eluate could be divided into at least two fractions.
- a constituent contained in one of the fractions was identified as 7 ⁇ ,15 ⁇ ,17 ⁇ -trihydroxy-4-pregnene-3,20-dione (the 1st compound of this invention) by the below described physicochemical properties obtained as a result of structural analysis.
- the yield was 9.6 mg.
- a constituent contained in the other fraction which was eluted earlier than above, for example, at 6 minutes as compared to 26 minutes for the above 1st compound was identified as 7 ⁇ -hydroxy-4-pregnene-3,15,20-trione (the 2nd compound of this invention) by the same method as above.
- the compound can be identified by the following physicochemical properties.
- the compound can be identified by the following physicochemical properties.
- 7 ⁇ ,15 ⁇ ,17 ⁇ -Trihydroxy-4-pregnene-3,20-dione is used as an intermediate for the synthesis of progesterone derivatives having ovulation-inhibiting activity as illustrated below.
- 7 ⁇ ,15 ⁇ -diacetyl-17 ⁇ -hydroxy-4-pregnene-3,20-dione can be prepared by using the compound as the intermediate according to the below described procedures. That is, the compound is reacted with acetic anhydride in pyridine to give the above acetylated derivative in the yield of 96%.
- disuccinic acid ester derivative or diglutaric acid ester is obtained respectively by reacting succinic anhydride or glutaric anhydride in place of acetic anhydride.
- Test of cell differentiation activity :
- the cell differentiation activity was measured by observing morphological change of the cells under a microscope. The results are indicated in Table 1.
- 7 ⁇ -Hydroxy-4-pregnene-3,15,20-trione also exhibits cell differentiation activity to some extent on the M1 cells derived from mouse as indicated in Table 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Steroid Compounds (AREA)
Abstract
Novel 7β-hydroxy-4-pregnene-3,20-dione derivatives are disclosed.
The group of these compounds has possibility of being utilized as an intermediate for the synthesis of progesterone derivatives having ovulation-inhibiting activity. These compounds themselves have also cell differentiation activity for M1 cells.
Description
This is a division of application Ser. No. 07/294,567 filed as PCT/JP88/00115, Feb. 5, 1988 now U.S. Pat. No. 5,028,722.
This invention relates to novel pregnene derivatives used as intermediates for the synthesis of progesterone derivatives having ovulation-inhibiting activity. A group of these compounds is expected to be used in the field of medicine. Cell differentiation activity is also found on a part of these compounds and hence utilization as drugs is also expected in this area.
A variety of pregnene derivatives has already been found to date. However, pregnene derivatives of this invention are novel compounds and biological activities of these compounds have naturally been unknown.
The present inventors have researched the action of microorganisms belonging to Acremonium sp., e.g. a strain of mold fungi, in a substrate of 4-pregnene- 3,20-dione. As a result, it has been found that two types of novel pregnene derivatives specified in this invention are produced.
The present inventors have further subjected one of the derivatives produced above to a reaction with acid anhydrides and found that esters of these derivatives can be obtained.
The pregnene derivatives of this invention can be used as intermediates for the manufacture of -™progesterone derivatives. These pregnene derivatives including the above mentioned esters exhibit also cell differentiation activity.
The pregnene derivatives of this invention are specified in claim 1, and representative examples of these derivatives have the following chemical names.
7β,15β,17α-Trihydroxy-4-pregnene-3,20-dione (the 1st compound of this invention described in claim 2).
7β-Hydroxy-4-pregnene-3,15,20-trione (the 2nd compound of this invention described in claim 3).
FIGS. 1-4 relate to the 1st compound of this invention. FIG. 1 illustrates an EI mass spectrum. FIG. 2 shows an infrared absorption spectrum. FIG. 3 shows a proton nuclear magnetic resonance spectrum. FIG. 4 illustrates a 13 C-nuclear magnetic resonance spectrum.
FIGS. 5-7 relate to the 2nd compound of this invention. FIG. 5 illustrates an EI mass spectrum. FIG. 6 illustrates a proton nuclear magnetic resonance spectrum. FIG. 7 shows a 13 C-nuclear magnetic resonance spectrum.
This invention is to provide a novel pregnene derivatives which is used as an intermediate for the manufacture of progesterone derivatives having progestin activities such as ovulation-inhibiting activity and also has itself cell differentiation activity. This invention will hereinafter be illustrated in detail by way of examples.
Acremonium strictum NN106 preserved in Hungarian National Institute of Hygiene (FERM P-9143), which is a strain of mold fungi was cultured with shaking in a medium containing carbon sources such as malt extract, peptone, nitrogen sources such as soybean meal, and inorganic salts. In carrying out the culture, the strain was inoculated on 100 ml of a culture medium having, for example, a below described composition in a Erlenmeyer flask of 500 ml volume. The culture was incubated and shaken simultaneously in a incubator with a rotary shaker at a rate of 200 rpm for 48 hours at 24° C.
______________________________________
Malt extract 30 g
Peptone 20 g
Soybean meal 10 g
Potassium phosphate, monobasic
5 g
Magnesium sulfate 5 g
Purified water 1000 ml
______________________________________
The above strain was deposited as FERM P-9143 in Fermentation Research Institute of the Agency of Industrial Science and Technology on Jan. 21, 1987.
4-Pregnene 3,20-dione as a substrate was dissolved in dimethylformamide in advance so as to obtain a substrate concentration of 0.1 g/ml.
To the culture solution obtained above, 2 ml of the above substrate solution was added and a reaction was carried out for 24-48 hours under the same conditions as above.
After completing the reaction, solid matters and cells were removed from the resultant culture solution by centrifugal separation. The resultant supernatant was extracted three times, each time using one third of its volume of ethyl acetate. The solvent was removed from the extracted solution with a rotary evaporator.
A crude fraction thus obtained was dissolved in a small amount of chloroform (or methanol) and passed through a silica gel column HPLC (20 mm diameter×300 mm length). The adsorbed fractions were eluted with a solvent mixture (chloroform:methanol=98:2) and fractionated.
The eluate could be divided into at least two fractions. A constituent contained in one of the fractions was identified as 7β,15β,17α-trihydroxy-4-pregnene-3,20-dione (the 1st compound of this invention) by the below described physicochemical properties obtained as a result of structural analysis. The yield was 9.6 mg.
A constituent contained in the other fraction which was eluted earlier than above, for example, at 6 minutes as compared to 26 minutes for the above 1st compound was identified as 7β-hydroxy-4-pregnene-3,15,20-trione (the 2nd compound of this invention) by the same method as above.
7β,15β,17α-Trihydroxy-4-pregnene-3,20-dione is represented by the chemical formula (II): ##STR1##
The compound can be identified by the following physicochemical properties.
______________________________________
(1) Appearance White powder
(2) Molecular weight 362
(3) Molecular formula C.sub.21 H.sub.30 O.sub.5
(4) Melting point 248-250° C.
(5) Specific rotation [α]D = +41.4°
(6) EI mass spectrum m/Z = 362.
See FIG. 1.
(7) Infrared absorption
See FIG. 2.
spectrum
(8) Proton nuclear magnetic
See FIG. 3.
resonance spectrum
(9) .sup.13 C-nuclear magnetic
See FIG. 4.
resonance spectrum
______________________________________
7β-Hydroxy-4-pregnene-3,15,20-trione is represented by the chemical formula (III): ##STR2##
The compound can be identified by the following physicochemical properties.
______________________________________
(1) Appearance White powder
(2) Molecular weight
344
(3) Molecular formula
C.sub.21 H.sub.28 O.sub.4
(4) Melting point 254-256° C.
(5) EI mass spectrum
m/Z = 344, See FIG. 5.
(6) Proton nuclear magnetic
See FIG. 6.
resonance spectrum
(7) .sup.13 C-nuclear magnetic
See FIG. 7.
resonance spectrum
______________________________________
7β,15β,17α-Trihydroxy-4-pregnene-3,20-dione is used as an intermediate for the synthesis of progesterone derivatives having ovulation-inhibiting activity as illustrated below. For example, 7β,15β-diacetyl-17α-hydroxy-4-pregnene-3,20-dione can be prepared by using the compound as the intermediate according to the below described procedures. That is, the compound is reacted with acetic anhydride in pyridine to give the above acetylated derivative in the yield of 96%.
In accordance with the above mentioned procedures, disuccinic acid ester derivative or diglutaric acid ester is obtained respectively by reacting succinic anhydride or glutaric anhydride in place of acetic anhydride. Test of cell differentiation activity:
The below described compounds were respectively allowed to act for 48 hours on myelogenic leukemia M1 cells derived from SL mouse.
The cell differentiation activity was measured by observing morphological change of the cells under a microscope. The results are indicated in Table 1.
TABLE 1
______________________________________
Cell
Differentiation
Test compound activity
______________________________________
7β,15β,17α-Trihydroxy-4-
++
pregnene-3,20-dione
(the 1st compound of this invention)
7β,15β-Diacetyl-17α-hydroxy-
+
4-pregnene-3,20-dione
7β,15β-Discuccinyl-17α-hydroxy-
+
4-pregnene-3,20-dione
7β,15β-Diglutaryl-17α-hydroxy-
+
4-pregnene-3,20-dione
______________________________________
7β-Hydroxy-4-pregnene-3,15,20-trione also exhibits cell differentiation activity to some extent on the M1 cells derived from mouse as indicated in Table 2.
TABLE 2 ______________________________________ Cell differentiation activity on M1 cells ______________________________________ Progesterone -- 7β-Hydroxy-4-pregnene-3,15,20-trione 50% ______________________________________
Reference to microorganisms deposited pursuant to Regulation 13 bis.
Deposit Organization: Fermentation Research Institute of the Agency of Industrial Science and Technology
Address: 1-3, Higashi-1-chome, Tsukuba-shi, Ibaraki-ken, JAPAN
Deposit No.: FERM P-9143
Date of Deposit: Jan. 21, 1987
Claims (2)
1. A method for preparing 7β,15β,17α-trihydroxy-4-pregnene-3,20-dione of the formula: ##STR3## wherein X is αHβOH, and Y is αOH, which comprises contacting 4-pregnene-3,20-dione with a microorganism having all of the identifying characteristics of the strain Acremonium strictum NN106 and isolating 7β,15β,17α-trihydroxy-4-pregnene-3,20-dione.
2. A method for preparing 7β-hydroxy-4-pregnene-3,15,20-trione of the formula: ##STR4## wherein X is ═O and Y is αH, which comprises contacting 4-pregnene-3,20-dione with a microorganism having all of the identifying characteristics of the strain Acremonium strictum NN106 and isolating 7β-hydroxy-4-pregnene-3,15,20-trione.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/436,582 US5164302A (en) | 1987-02-06 | 1989-11-15 | Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62024597A JPS63192799A (en) | 1987-02-06 | 1987-02-06 | 7beta,15beta,17alpha-trihydroxy-4-pregnene-3,20-dione |
| JP62-024597 | 1987-02-06 | ||
| JP62147017A JPS63313798A (en) | 1987-06-15 | 1987-06-15 | Novel 7beta-hydroxy-4-pregnene-3,15,20-trione |
| JP62-147017 | 1987-06-15 | ||
| US07/436,582 US5164302A (en) | 1987-02-06 | 1989-11-15 | Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/294,567 Division US5028722A (en) | 1987-02-06 | 1988-02-05 | Novel 7 β-hydroxy-4-pregnene-3,20-dione derivatives and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5164302A true US5164302A (en) | 1992-11-17 |
Family
ID=27284720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/436,582 Expired - Fee Related US5164302A (en) | 1987-02-06 | 1989-11-15 | Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US5164302A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102911232A (en) * | 2012-11-02 | 2013-02-06 | 湖北丹江口丹澳医药化工有限公司 | Progesterone preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879280A (en) * | 1955-05-27 | 1959-03-24 | Olin Mathieson | 15-hydroxy progesterones |
| US2962512A (en) * | 1959-05-26 | 1960-11-29 | American Cyanamid Co | Oxidation of steroids and products thereof |
| US3031477A (en) * | 1956-02-24 | 1962-04-24 | Olin Mathieson | Delta4-pregene-7alpha, 17alpha, 21-triol-3, 20-dione and esters thereof |
| US3125495A (en) * | 1964-03-17 | Microbial preparation of |
-
1989
- 1989-11-15 US US07/436,582 patent/US5164302A/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3125495A (en) * | 1964-03-17 | Microbial preparation of | ||
| US2879280A (en) * | 1955-05-27 | 1959-03-24 | Olin Mathieson | 15-hydroxy progesterones |
| US3031477A (en) * | 1956-02-24 | 1962-04-24 | Olin Mathieson | Delta4-pregene-7alpha, 17alpha, 21-triol-3, 20-dione and esters thereof |
| US2962512A (en) * | 1959-05-26 | 1960-11-29 | American Cyanamid Co | Oxidation of steroids and products thereof |
Non-Patent Citations (7)
| Title |
|---|
| ATCC Catalogue of Fungi, 1981, pp. 6 and 86. * |
| ATCC Catalogue of Fungi, 1987, pp. 4 6. * |
| ATCC Catalogue of Fungi, 1987, pp. 4-6. |
| Chem. Abstracts, vol. 55, No. 17, Aug. 21, 1961; Tsuda et al; "Microbiological hydroxylation of steroids". X. 7β,15β-dihydroxypregn-4-ene-3,20-dione. |
| Chem. Abstracts, vol. 55, No. 17, Aug. 21, 1961; Tsuda et al; Microbiological hydroxylation of steroids . X. 7 ,15 dihydroxypregn 4 ene 3,20 dione. * |
| Journal of Chemical Ecology, vol. 13, No. 1, Jan. 1987, pp. 35 38; Meinwald et al, Defensive steroids from carrion beetle. * |
| Journal of Chemical Ecology, vol. 13, No. 1, Jan. 1987, pp. 35-38; Meinwald et al, "Defensive steroids from carrion beetle." |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102911232A (en) * | 2012-11-02 | 2013-02-06 | 湖北丹江口丹澳医药化工有限公司 | Progesterone preparation method |
| CN102911232B (en) * | 2012-11-02 | 2015-03-11 | 湖北丹澳药业有限公司 | Progesterone preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4416985A (en) | Process for preparing 3β,7β-dihydroxy-Δ5 -steroids | |
| US5079377A (en) | Novel androst-4-ene-3,17-dione derivatives and method for preparing same | |
| US5164302A (en) | Method for preparing 7β-hydroxy-4-pregnene-3,20-dione derivatives | |
| US5028722A (en) | Novel 7 β-hydroxy-4-pregnene-3,20-dione derivatives and method for preparing same | |
| Laskin et al. | Microbial hydroxylation of estrone and estradiol in the 6β-, 7α-, and 15α-positions | |
| US4301246A (en) | Process for chenodeoxycholic acid production | |
| US4039381A (en) | Composition of matter and process | |
| US3909362A (en) | Microbial production of anti-microbial 2H-pyran-2-ones | |
| US4429041A (en) | Process of producing 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxylic acid | |
| US4336332A (en) | Process for the manufacture of hydroxylated steroids | |
| EP0154407B1 (en) | Methods of preparing 11 beta, 17 alpha, 20, 21-tetra-hydroxy steroids and corresponding 11 beta, 17 alpha, 21-trihydroxy-20-oxo steroids | |
| HU176627B (en) | Process for producing 3a-alpha-h-4-alpha-bracket-3-comma above-propionic acid-bracket closed-7a-beta-methyl-hexahydro-1,5-indanedione by microbiologicaltransformation of sytosterine | |
| US2819200A (en) | Microbial oxygenation of steroids at carbon no. 21 | |
| US3880895A (en) | Hydroxylation of d-13-alkyl-17{60 -ethynyl-hydroxygon-4-en-3-one and derivatures thereof | |
| US2819201A (en) | Microbial oxygenation of steroids in the 21 position | |
| US2813060A (en) | 17alpha oxygenation of steroids by sporormia | |
| US4304860A (en) | Process for the microbial transformation of steroids | |
| US4284720A (en) | Process for the preparation of 19-hydroxy steroids of the androstane and pregnane series | |
| JPH0481435B2 (en) | ||
| JPH0246294A (en) | Production of angnocyclinone from streptomyces microorganism and production thereof | |
| JPH0152399B2 (en) | ||
| US3030278A (en) | Production of hydrocortisone by multiple fermentation | |
| US2875133A (en) | Preparation of 21-hydroxy steroids | |
| US3285829A (en) | Process for producing 16alpha-hydroxy-steroids using nocardia it alica | |
| WO1996012034A1 (en) | A microbiological process for the preparation of 17beta-carboxy substituted 3-oxo-4-azasteroids and the use of such products as inhibitors of the enzyme 5alpha-reductase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19961120 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |